





PROGRESS AND PERSPECTIVES

Thursday, April, 7 ^t	, 2010	J
---------------------------------	--------	---

PRELIMINARY PROGRAM

COSMOCAIXA BARCELONA. C/ISAAC NEWTON, 26

q				/ e		

- 9:30 SESSION 1: IMMUNOLOGY AND CANCER THERAPY Chairs: Ramon Alemany (ProCURE, ICO) and Joaquín Arribas (VHIO)
- Chemoimmunotherapy a New Approach to treat Refractory Prostate and Liver Cancers Michael Karin, University of California San Diego, USA
- 10:15 Targeting the Heterogeneity of Cancer with Individualized Neo-epitope Vaccines -**Preclinical and Clinical insight Sebastian Kreiter**, Johannes Gutenberg University, Mainz, Germay
- 11:00 Viroimmunotherapy for Cancer Treatment Ramon Alemany, ProCURE, Catalan Institute of Oncology (ICO), Barcelona, Spain
- 11:30 Coffee break
- 12:00 SESSION 2: GENETICS, EPIGENETICS AND MECHANISMS Chairs: Oriol Casanovas (ProCURE, ICO) and Violeta Serra (VHIO)
- **Cancer Pharmacoepigenetics: Genes and Drugs** Manel Esteller, Cancer Epigenetics and Biology Program, IDIBELL, L'Hospitalet de Llobregat, Spain
- 12:45 Searching for new strategies to treat T-Acute Lymphoblastic Leukemia Anna Bigas, Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain
- 13:30 Lunch
- THINK-TANK: CAVEATS/OPPORTUNITIES TO IMPROVE THE TRANSLATION TO THE 14:30

Chairs: Josep Corbella (La Vanguardia), Joaquín Arribas (VHIO) and Alberto Villanueva (ProCURE, ICO)

COORGANIZED BY:
























PROGRESS AND PERSPECTIVES

Thursday, April, 7th, 2016

PRELIMINARY PROGRAM

COSMOCAIXA BARCELONA. C/ISAAC NEWTON, 26

- 16:30 Coffee break
- 17:00 SESSION 3: MOLECULAR CLASSIFICATION AND THERAPEUTIC TARGETING Chairs: Ramon Salazar (ICO) and Josep Tabernero (VHIO)
- 17:00 Dissecting Colorectal Cancer in Multiple Subtypes Rodrigo Dienstmann, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 17:30 New Molecular Landscape in CRC. New Therapeutic Landscape? Ramon Salazar, Catalan Institute of Oncology (ICO), Barcelona, Spain
- Identification and Therapeutic Targeting of Poor Prognosis Subtypes in Colorectal 18:00 **Eduard Batlle**, Institute for Research in Biomedicine (IRB), Barcelona, Spain
- 18:30 Microenvironment-mediated Chemotherapy resistance in Colorectal Cancer David G Molleví, Catalan Institute of Oncology (ICO), Barcelona, Spain
- 19:00 Welcome Cocktail and CosmoCaixa visit

COORGANIZED BY:
























PROGRESS AND PERSPECTIVES

Friday, April, 8th, 2016

PRELIMINARY PROGRAM

COSMOCAIXA BARCELONA. C/ISAAC NEWTON, 26

8:30	SESSION 4: CANCER OMICS AND THERAPEUTICS
	Chairs: Miquel Angel Puiana (ProCURE, ICO) and Héctor G Palmer (VHIO)

8:30 Genomic Analysis of Therapy Response and Resistance Elaine Mardis, McDonnell Genome Institute, Washington University, USA

9:15	Systemic Approaches to Identify Cancer Targets
	William Hahn, Broad Institute, Dana-Farber Integrative Cancer Biology Program, Cambridge, USA

10:00 Coffee break

Patient-derived Tumour Explants as a Robust Pharmacogenomic Platform for Pre-clinic 10:30 **Drug Testing** Carlos Caldas, University of Cambridge, UK

Co-Activation of STAT3 and Src-Notch Pathways in EGFR Mutant Lung Cancer 11:15 Rafael Rosell, Catalan Institute of Oncology (ICO), Barcelona, Spain

Diagnostic and Therapeutic Implications of unconventional Protein secretion in Cancer 12:30 Josep Villanueva, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

Lunch 13:00

SESSION 5: MOLECULAR SIGNALING AND MODELS 14:00 Chairs: Alberto Villanueva (ProCURE, ICO) and Josep Villanueva (VHIO)

A Vulnerability of BRAF Resistant Melanoma with Potential Clinical Utility 14:00 René Bernards, Netherlands Cancer Institute (NKI), Amsterdam, The Netherlands

Targeting the MAPK Pathway in K-RAS Mutant Tumors. Challenges and Opportunities 14:45 Mariano Barbacid, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain

COORGANIZED BY:
























PROGRESS AND PERSPECTIVES

Friday, April, 8th, 2016

PRELIMINARY PROGRAM

COSMOCAIXA BARCELONA. C/ISAAC NEWTON, 26

- 15:30 Restoration of DNA Homologous Recombination (HR) Funcionality as a major Mechanism of PARP inhibitor Resistance in HR-deficient Breast Cancer Violeta Serra, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- 16:00 Otrho-xenograft Models and Personalized Medicine Alberto Villanueva, (ProCURE, ICO), Barcelona, Spain
- 16:30 Coffee break
- 17:00 SESSION 6: STEM CELLS AND MALIGNIZATION Chairs: David G Molleví (ProCURE, ICO) and Oriol Casanovas (ProCURE, ICO)
- A Stem Cell-like Program in Therapeutic Resistance 17:00 Miguel Angel Pujana, ProCURE, ICO, Barcelona, Spain
- The Role of Cancer Stem Cells in the Inhibition of mTOR signaling in HCC 17:30 George Thomas, Bellvitge Biomedical Research Institute, IDIBELL, L'Hospitalet de Llobregat, Spain
- New Pre-clinical Models to study Target-directed Drugs in advanced Colorectal Cancer 18:00 Hector G Palmer, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
- Therapeutic Resistance to Antiangiogenics: Evasion and Escape 18:30 Oriol Casanovas, ProCURE, ICO, Barcelona, Spain
- 19:00 Closing and Conclusions

COORGANIZED BY:















